Schaper Benz & Wise Investment Counsel Upped By $814,936 Its Regeneron (REGN) Position; SUNRISE COMMUNICATIONS GROUP LTD ORDINAR (SNMMF) Sellers Increased By 1039.15% Their Shorts

June 23, 2018 - By Winifred Garcia

Sunrise Communications Group AG (OTCMKTS:SNMMF) Logo

SUNRISE COMMUNICATIONS GROUP LTD ORDINAR (OTCMKTS:SNMMF) had an increase of 1039.15% in short interest. SNMMF’s SI was 320,100 shares in June as released by FINRA. Its up 1039.15% from 28,100 shares previously. With 200 avg volume, 1601 days are for SUNRISE COMMUNICATIONS GROUP LTD ORDINAR (OTCMKTS:SNMMF)’s short sellers to cover SNMMF’s short positions. The SI to SUNRISE COMMUNICATIONS GROUP LTD ORDINAR’s float is 0.95%. It closed at $80.14 lastly. It is down 0.00% since June 23, 2017 and is . It has underperformed by 12.57% the S&P500.

Schaper Benz & Wise Investment Counsel Inc increased Regeneron (REGN) stake by 18.23% reported in 2018Q1 SEC filing. Schaper Benz & Wise Investment Counsel Inc acquired 2,369 shares as Regeneron (REGN)’s stock declined 9.59%. The Schaper Benz & Wise Investment Counsel Inc holds 15,367 shares with $5.29M value, up from 12,998 last quarter. Regeneron now has $35.77B valuation. The stock increased 0.89% or $2.93 during the last trading session, reaching $331.97. About 557,320 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 35.54% since June 23, 2017 and is downtrending. It has underperformed by 48.11% the S&P500. Some Historical REGN News: 16/05/2018 – Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO; 16/05/2018 – Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis; 21/03/2018 – Regeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease; 16/05/2018 – REGENERON, SANOFI: POSITIVE DATA FOR CEMIPLIMAB; 21/03/2018 – ALNYLAM PHARMACEUTICALS INC – ALNYLAM WILL LEVERAGE ITS RNAI THERAPEUTICS PLATFORM TO IDENTIFY COMPOUNDS DIRECTED TO TARGET; 11/05/2018 – BAYER AG BAYGn.DE – BAYER RECEIVES APPROVAL FOR EYLEA® IN CHINA; 03/05/2018 – REGENERON PHARMACEUTICALS INC SEES 2018 CAPITAL EXPENDITURES $420 MLN-$480 MILLION; 10/03/2018 – REGENERON, SANOFI SAY LOWER PRICE CONTINGENT ON INSURERS REMOVING BARRIERS TO ACCESS FOR HIGH-RISK HEART PATIENTS; 03/04/2018 – REG-Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma; 21/05/2018 – New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Sever

More news for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were recently published by:, which released: “Sell Kraft-Heinz At $64-65 – Cramer’s Lightning Round (6/21/18)” on June 22, 2018.‘s article titled: “Inovio Pharma (INO) Reports Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO …” and published on June 21, 2018 is yet another important article.

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 11 have Buy rating, 1 Sell and 21 Hold. Therefore 33% are positive. Regeneron Pharmaceuticals Inc. had 127 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by JP Morgan with “Neutral” on Wednesday, January 24. BMO Capital Markets maintained the shares of REGN in report on Monday, October 16 with “Hold” rating. The company was maintained on Monday, April 4 by Leerink Swann. The rating was maintained by UBS with “Buy” on Thursday, September 21. On Tuesday, September 1 the stock rating was initiated by Raymond James with “Outperform”. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Hold” rating by J.P. Morgan on Monday, August 14. Leerink Swann maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) rating on Friday, February 9. Leerink Swann has “Outperform” rating and $502 target. The rating was maintained by Chardan Capital Markets with “Sell” on Monday, November 7. The firm has “Buy” rating given on Tuesday, January 19 by Roth Capital. The company was downgraded on Wednesday, April 20 by Wells Fargo.

Schaper Benz & Wise Investment Counsel Inc decreased Paychex (NASDAQ:PAYX) stake by 6,098 shares to 203,575 valued at $12.54 million in 2018Q1. It also reduced American Express (NYSE:AXP) stake by 3,487 shares and now owns 153,061 shares. Intel (NASDAQ:INTC) was reduced too.

Investors sentiment decreased to 1.05 in Q1 2018. Its down 0.12, from 1.17 in 2017Q4. It is negative, as 70 investors sold REGN shares while 158 reduced holdings. 71 funds opened positions while 169 raised stakes. 69.33 million shares or 0.23% more from 69.17 million shares in 2017Q4 were reported. Westwood Gp Inc Inc holds 0.02% or 6,924 shares in its portfolio. Jefferies Group Llc holds 0% or 1,586 shares in its portfolio. The New York-based Adirondack Tru Co has invested 0.03% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Rhumbline Advisers holds 0.1% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) or 143,371 shares. Prentiss Smith And holds 3.57% or 19,753 shares. First Interstate Bank accumulated 2,183 shares or 0.17% of the stock. Strs Ohio holds 48,532 shares. Pictet & Cie (Europe) Sa holds 1,486 shares or 0.08% of its portfolio. Advisor Limited Co holds 0.06% or 869 shares in its portfolio. Raymond James Fin Ser Inc has invested 0.01% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). 32,831 are held by Profund Advsrs Lc. Peak6 Invests LP holds 0.01% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 4,713 shares. Hudock Capital Group Ltd Company holds 0.01% or 90 shares. Geode Cap Mgmt reported 935,976 shares stake. Boston Advsr Ltd Company owns 0.06% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 6,716 shares.

Since February 9, 2018, it had 0 insider buys, and 6 selling transactions for $48.41 million activity. Sanofi also sold $37.61M worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Shares for $325,600 were sold by GOLDSTEIN JOSEPH L on Friday, February 9. Shares for $5.72M were sold by SING GEORGE L. $3.37M worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was sold by STAHL NEIL on Wednesday, May 23.

Sunrise Communications Group AG, together with its subsidiaries, provides telecommunications services to residential and business customers, and other carriers in Switzerland. The company has market cap of $3.61 billion. The firm offers mobile voice and data on postpaid and prepaid basis, landline voice and Internet, and Internet protocol television services; and system integration and managed services; and voice hubbing services based on the proprietary landline network. It has a 7.1 P/E ratio. It also provides other value-added services, such as international calls, roaming, and device insurance services; and mobile phones, tablets, and other hardware devices.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: